Transgene SA

Transgene SA

Transgene SA

Overview
Date Founded

1986

Headquarters

400 Boulevard Gonthier d'Andernach,Parc d'Innovation,Illkirch-Graffenstaden,Strasbourg, Grand Est 67405

Type of Company

Public

Employees (Worldwide)

160

Industries

Biotechnology
Pharmaceuticals

Company Description

Transgene SA is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of immunotherapies for the treatment of cancer and infectious diseases. Its products include TG4001, TG6002, BT-001 and TG4050. The company was founded in December 1979 and is headquartered in Strasbourg, France.

Contact Data
Trying to get in touch with decision makers at Transgene SA? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chairman & Chief Executive Officer

Vice President Quality & Deputy Chief Executive Officer

Vice President & Chief Financial Officer

Chief Scientific Officer & Executive Vice President

Vice President-Corporate Development

Vice President, Corporate Development & Medical Affairs

Vice President, Human Resources Director

Vice President, Corporate Secretary & General Counsel

Vice President Medical Affairs & Chief Medical Officer (CMO)

Director-Investor Relations

Board of Directors

Chairman & Chief Executive Officer at Transgene SA

Founder at bioMérieux SA

Operating Advisor, Cd&R Funds at Clayton, Dubilier & Rice Holdings LP

Managing Director at Habert Dassault Finance SAS

Chief Executive Officer at TSGH SAS

President & Director at Synergie Lyon Cancer

Group Manager, Tumour Immunology & Immunotherapy at Institut Gustave Roussy EURL

Chief Financial Officer at Institut Mérieux SA

Former Vice President-Strategy, External Innovation & Science Policy at Sanofi

Chief Executive Officer at Genoscience Pharma

Paths to Transgene SA
Potential Connections via
Relationship Science
You
Transgene SA
Recent Transactions
Details Hidden

Tasly Biopharmaceuticals Co., Ltd. purchases Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd. from Transgene SA

Details Hidden

Advanced Bioscience Laboratories, Inc., ABL Europe SAS purchase Transgene SA /Biopharmaceutical Manufacturing Unit from Transgene SA

Details Hidden

Advanced Bioscience Laboratories, Inc. purchases Platine Pharma Services SAS from Transgene SA

Transaction Advisors
Investment Advisor

Advised onTasly Biopharmaceuticals Co., Ltd. purchases Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd. from Transgene SA

Investment Advisor

Advised onAdvanced Bioscience Laboratories, Inc., ABL Europe SAS purchase Transgene SA /Biopharmaceutical Manufacturing Unit from Transgene SA

Chief Executive Officer

Advised onAdvanced Bioscience Laboratories, Inc., ABL Europe SAS purchase Transgene SA /Biopharmaceutical Manufacturing Unit from Transgene SA

Investment Advisor

Advised onAdvanced Bioscience Laboratories, Inc., ABL Europe SAS purchase Transgene SA /Biopharmaceutical Manufacturing Unit from Transgene SA

Advisors & Consultants
Advisor

Professional at Citigate Dewe Rogerson Ltd.

Advisor

Professional at Citigate Dewe Rogerson Ltd.

Advisor

Professional at Citigate Dewe Rogerson Ltd.

Clients

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Ascend Biopharmaceuticals Ltd. is a cancer immunotherapy company that develops medicines to treat primary, recurrent, and metastatic cancers. It offers pipeline strategy that focuses on a number of oncology and dermato-oncology settings. The company was founded by Clement Leong on September 10, 2003 and is headquartered in Melbourne, Australia.

Key Stats and Financials As of 2019
Market Capitalization
$223M
Total Enterprise Value
$116M
Earnings Per Share
$-0.26
EBITDAMargin
-451.61%
Enterprise Value / Sales
15.29x
TEVNet Income
-5.41x
Debt TEV
0.16x
Three Year Compounded Annual Growth Rate Of Revenue
41.54%
Five Year Compounded Annual Growth Rate Of Revenue
21.72%
Revenue
$7.6M
Net Profit
$-21.5M
EBITDA
$-34.3M
Total Debt
$18.6M
Total Equity
$75.1M
Investments
Details Hidden

ElsaLys Biotech SAS provides therapeutic monoclonal antibody player services. It involves in cellular events at the core of the pathological process: immune response, angiogenesis, survival, proliferation, adhesion and migration. The company also designs and develops a new generation of antibodies that target tumors and their immune microenvironment. ElsaLys Biotech was founded by Christine Guillen, Thierry Menguy, Vanessa Duong, and Martine Brandt in 2013 and is headquartered in Lyon, France.

Suppliers
Sanofi Pharmaceuticals | Paris, France

Sanofi, a diversified global healthcare leader, discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With nearly 100,000 dedicated professionals in more than 100 countries, Sanofi is devoted to advancing healthcare around the world. Sanofi US, with headquarters in Bridgewater, New Jersey, along with our vaccines division, Sanofi Pasteur, employs more than 11,400 professionals throughout the country. At Sanofi, we work for what really matters: health

Prescient Therapeutics Ltd. Pharmaceuticals | South Melbourne, Australia

Prescient Therapeutics Ltd. is a biopharmaceutical company. The firm engages in the discovery and development of novel immunotherapeutic products for the treatment of chronic infectious diseases and cancer. It develops immune therapeutics based upon its Co-X-Gene and fowlpox virus delivery technologies. The company was founded on May 22, 1986 and is headquartered in South Melbourne, Australia.

Valneva SE Hospitals & Patient Services | Saint-herblain, France

Valneva SE is a biotech company. The firm engages in the development, production and marketing of vaccine and preventive medicine. It operates through the following segments: Commercialized Vaccines, Technologies and Services and Vaccine Candidates. The Commercialized Vaccines segment includes currently marketed vaccines of the group such as JEV and DUKORAL. The Technologies and Services segment regroups services and inventions in commercialization stage. The Vaccine Candidates segment consists of proprietary research and development programs aiming to generate new approvable products. The company was founded on April 7, 1999 and is headquartered in Saint-Herblain, France.

Competitors
Alnylam Pharmaceuticals, Inc. Pharmaceuticals - Cambridge, Massachusetts

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Arbutus Biopharma Corp. Pharmaceuticals - Burnaby, Canada

Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Transgene SA. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Transgene SA's profile does not indicate a business or promotional relationship of any kind between RelSci and Transgene SA.